Approaching the sensitized lung patient: risk assessment for donor acceptance.
C1q
HLA antibodies
allosensitization
donor-specific antibodies (DSA)
lung transplant
risk stratification
titer
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
27
11
2020
accepted:
14
05
2021
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
8
1
2022
Statut:
ppublish
Résumé
The presence of HLA antibodies is widely recognized as a barrier to solid organ transplantation, and for lung transplant candidates, it has a significant negative impact on both waiting time and waiting list mortality. Although HLA antibodies have been associated with a broad spectrum of allograft damage, precise characterization of these antibodies in allosensitized candidates may enhance their accessibility to transplant. The introduction of Luminex-based single antigen bead (SAB) assays has significantly improved antibody detection sensitivity and specificity, but SAB alone is not sufficient for risk-stratification. Functional characterization of donor-specific antibodies (DSA) is paramount to increase donor accessibility for allosensitized lung candidates. We describe here our approach to evaluate sensitized lung transplant candidates. By employing state-of-the-art technologies to assess histocompatibility and determine physiological properties of circulating HLA antibodies, we can provide our Clinical Team a better risk assessment for lung transplant candidates and facilitate a "road map" to transplant. The cases presented in this paper illustrate the "individualized steps" taken to determine calculated panel reactive antibodies (cPRA), titer and complement-fixing properties of each HLA antibody present in circulation. When a donor is considered, we can better predict the risk associated with potentially crossing HLA antibodies, thereby allowing the Clinical Team to approach allosensitized lung patients with an individualized medicine approach. To facilitate safe access of sensitized lung transplant candidates to potential donors, a synergy between the histocompatibility laboratory and the Clinical Team is essential. Ultimately, donor acceptance is a decision based on several parameters, leading to a risk-stratification unique for each patient.
Identifiants
pubmed: 34992848
doi: 10.21037/jtd-2021-21
pii: jtd-13-11-6725
pmc: PMC8662510
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6725-6736Informations de copyright
2021 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: https://dx.doi.org/10.21037/jtd-2021-21). The series “Lung Transplantation: Past, Present, and Future” was commissioned by the editorial office without any funding or sponsorship. All authors have no other conflicts of interest to declare.
Références
Am J Transplant. 2015 Feb;15(2):417-26
pubmed: 25612494
Am J Transplant. 2015 Sep;15(9):2421-30
pubmed: 25930984
J Clin Invest. 2017 Jun 30;127(7):2492-2504
pubmed: 28604384
PLoS Med. 2018 May 25;15(5):e1002572
pubmed: 29799874
N Engl J Med. 2013 Sep 26;369(13):1215-26
pubmed: 24066742
Am J Transplant. 2017 May;17(5):1380-1388
pubmed: 28173620
Hum Immunol. 2005 Apr;66(4):378-86
pubmed: 15866701
J Heart Lung Transplant. 2007 Jun;26(6):565-71
pubmed: 17543778
Curr Opin Organ Transplant. 2019 Feb;24(1):20-30
pubmed: 30507703
Transplantation. 2015 Jul;99(7):1416-22
pubmed: 26038872
Medicine (Baltimore). 2016 Mar;95(11):e3094
pubmed: 26986147
Am J Transplant. 2014 Apr;14(4):849-56
pubmed: 24666831
Curr Opin Organ Transplant. 2013 Aug;18(4):470-7
pubmed: 23695596
J Heart Lung Transplant. 2015 Nov;34(11):1415-22
pubmed: 26169666
J Heart Lung Transplant. 2018 May;37(5):537-547
pubmed: 29452978
J Heart Lung Transplant. 2005 Jul;24(7 Suppl):S249-54
pubmed: 15993781
J Heart Lung Transplant. 2011 Nov;30(11):1221-7
pubmed: 21821435
N Engl J Med. 2018 Dec 27;379(26):2580-2582
pubmed: 30586534
Transplantation. 2013 Mar 15;95(5):761-5
pubmed: 23296148
Transplantation. 2014 Mar 15;97(5):595-601
pubmed: 24162250
Am J Transplant. 2018 Dec;18(12):2934-2944
pubmed: 29659162
Ann Am Thorac Soc. 2019 Jul;16(7):846-852
pubmed: 30763122
Am J Transplant. 2019 Feb;19(2):381-390
pubmed: 29981209
Am J Respir Crit Care Med. 2016 Sep 1;194(5):596-606
pubmed: 26967790
J Heart Lung Transplant. 2013 Jan;32(1):98-105
pubmed: 23142561
Transpl Immunol. 2017 Dec;45:8-14
pubmed: 28782692
J Heart Lung Transplant. 2017 Jul;36(7):787-796
pubmed: 28318744
BMC Pulm Med. 2018 Mar 12;18(1):45
pubmed: 29529999
J Heart Lung Transplant. 2014 Dec;33(12):1273-81
pubmed: 25130554
Transplantation. 2013 Jan 15;95(1):19-47
pubmed: 23238534
Am J Transplant. 2011 May;11(5):896-906
pubmed: 21521465
J Am Soc Nephrol. 2016 Jan;27(1):293-304
pubmed: 26293822
Ann Transplant. 2019 Jun 28;24:383-392
pubmed: 31249284
J Heart Lung Transplant. 2010 Sep;29(9):973-80
pubmed: 20558084
J Immunol Res. 2017;2017:7903471
pubmed: 28373996
Pediatr Nephrol. 2018 Jan;33(1):167-174
pubmed: 28918487